Form 4: Perspective Therapeutics Director Frank Morich Granted Stock Options

Director Frank Morich received a grant of 50,000 stock options in Perspective Therapeutics, Inc.

Summary

• Frank Morich, a director of Perspective Therapeutics, Inc., was granted 50,000 stock options on March 3, 2025.
• The options have an exercise price of $2.46.
• The options vest in full on March 3, 2026, contingent upon continued service.
• The options expire on March 3, 2035.
• Morich also has granted power of attorney to Johan (Thijs) Spoor, Juan Graham, Jonathan Hunt and Chris Nenno to execute and file necessary SEC forms on his behalf.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management and shareholder interests.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service.

Future Outlook

NA

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded companies, particularly in the biotech sector.
• The size of the grant (50,000 shares) would need to be compared to grants made to directors at comparable companies to determine if it is above or below industry averages.
• Companies like Amgen, Gilead, and Biogen often use stock options as part of their compensation strategy for board members.

Stakeholder Impact

• Shareholders may view the option grant as a positive incentive for the director to increase company value.
• Employees may see this as a standard part of executive compensation.

Key Dates